Regeneron Pharmaceuticals, Inc.
Regeneron Reports Strong Q3 2024 Results with 11% Revenue Growth and Dupixent COPD Approval
Summary
Regeneron Pharmaceuticals, Inc. announced its financial and operating results for the third quarter of 2024, reporting an 11% increase in total revenues to $3.72 billion compared to the same period in 2023. The company saw notable growth in the sales of its key products, including a 23% increase in Dupixent sales to $3.82 billion. GAAP diluted EPS increased by 30% to $11.54, while non-GAAP diluted EPS rose by 8% to $12.46. The FDA approved Dupixent for treating chronic obstructive pulmonary disease (COPD) in the U.S., marking the first-ever biologic therapy for this indication. Regeneron also provided updates on its clinical pipeline, including positive results from pivotal trials for Dupixent in chronic spontaneous urticaria and bullous pemphigoid. The company further revised its financial guidance for 2024.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement